Question 1

Does Jacobs Levy Equity Management own PTGX stock?

Accepted Answer

No. Jacobs Levy Equity Management exited its PTGX (Protagonist Therapeutics) position in Q2 2025. Its Q1 2025 13F listed 128,654 shares worth $6.2M.

Question 2

How many shares of PTGX does Jacobs Levy Equity Management own?

Accepted Answer

None since Q2 2025, when Jacobs Levy Equity Management exited the position. Its Q1 2025 13F listed 128,654 shares worth $6.2M.

Question 3

What is Jacobs Levy Equity Management's PTGX position worth?

Accepted Answer

Jacobs Levy Equity Management's PTGX position was worth $6.2M in its Q1 2025 13F, before the exit in Q2 2025.

Question 4

Is Jacobs Levy Equity Management buying or selling PTGX?

Accepted Answer

In Q2 2025, Jacobs Levy Equity Management exited its entire PTGX position.

Question 5

When did Jacobs Levy Equity Management first buy PTGX?

Accepted Answer

Jacobs Levy Equity Management already held PTGX in its Q4 2018 13F, the earliest on record, and listed it in 17 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price
2025-Q2 Latest	Exited	0	-100.0%	$0	0.0%	$55.27
2025-Q1	Unchanged	128,654	0.0%	$6.2M	0.0%	$48.36
2024-Q4	Unchanged	128,654	0.0%	$5M	0.0%	$38.60
2024-Q3	Decreased	128,654	-0.3%	$5.8M	0.0%	$45.00